Nemonapride

Drug Profile

Nemonapride

Alternative Names: Emirace; Emonapride; YM 09151; YM 09151-2

Latest Information Update: 06 Jun 2007

Price : $50

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Negma
  • Class Antipsychotics; Benzamides; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Schizophrenia

Most Recent Events

  • 03 May 2007 Negma has been acquired and merged into Wockhardt
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 30 Jan 2001 Discontinued-II in Schizophrenia in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top